← Human Trials & Peer-Reviewed Studies
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Plain-language guide to PMID 30341767 (2019): randomized controlled trial study of Insulin Glargine and Liraglutide in 75 patients, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 30341767
- Journal
- Hepatology (Baltimore, Md.)
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Yan J et al. (21 authors)
- DOI
- 10.1002/hep.30320
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Glargine and Liraglutide in the context of fatty liver & elevated liver enzymes.
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin glargine in this 26-week trial.
Why It Was Studied
The primary endpoint was the change in intrahepatic lipid (IHL) from baseline to week 26 as quantified by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF).
Secondary endpoints included changes in abdominal adiposity (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT]), glycated hemoglobin, and body weight from baseline to week 26.
Who Took Part
The abstract describes 75 patients taking part.
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.
What Was Measured
The primary endpoint was the change in intrahepatic lipid (IHL) from baseline to week 26 as quantified by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF).
Secondary endpoints included changes in abdominal adiposity (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT]), glycated hemoglobin, and body weight from baseline to week 26.
PubMed files the paper under topics including Blood Glucose, Comorbidity, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Glargine, Linear Models and Lipid Metabolism.
What This Means in Plain Language
The paper is a randomized study of Insulin Glargine and Liraglutide in 75 patients in people with fatty liver & elevated liver enzymes.
The publication is from 2019 (Hepatology (Baltimore, Md.)), a journal based in United States.
More context: the Insulin Glargine compound page and the Liraglutide compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compounds
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
- Fatty liver & elevated liver enzymes research
- Insulin Glargine in the library
- Liraglutide in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.